ADXNAddex Therapeutics Ltd American Depositary Shares

ADRCNasdaq (XNAS)·USD

Identity

Security key: 11337
Ticker: ADXN
Type: ADRC — American Depository Receipt Common
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2020-01-29
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: ADXN

Detail

Enriched 2026-08-14 20:47

Market cap: $7,531,771.8
Shares outstanding (class): 1,822,121
Shares outstanding (weighted): 1,265,844
SIC: —
Employees: 3
Location: —
Homepage: https://www.addextherapeutics.com
Description: Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

Market cap and share counts drift.

Funds holding this security

as of 2026-03-31

No reported positions at this date.

Positions are reached through OpenFIGI-resolved ISINs. A security with no resolved ISIN cannot be found this way even if funds do hold it.

Funds holding this security

Identifiers

master.security_identifier

TICKERADXN
FIGI_COMPOSITEBBG00R48ST95
FIGI_SHARE_CLASSBBG00R48SV18
CIK0001574232

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Addex Therapeutics is a biopharmaceutical company developing drugs for neurological disorders, fitting the biotechnology industry.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.